Tandem Diabetes Other Stockholder Equity Over Time
| TNDM Stock | USD 30.63 0.59 1.89% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tandem Diabetes Performance and Tandem Diabetes Correlation. Tandem |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare Tandem Diabetes Care and related stocks such as DexCom Inc, Inspire Medical Systems, and Shockwave Medical Other Stockholder Equity Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | 4 M | 495.6 M | 522.6 M | 559.5 M | 638 M | 776.8 M | 905.7 M | 1.1 B | 1.5 B | 1.6 B | 2 B | 1.9 B | 1.7 B | 1.1 B | 1.1 B |
| INSP | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 126.6 M | 310.9 M | 319.9 M | 467 M | 508.5 M | 820.3 M | 917.1 M | 478.1 M |
| PEN | (50.1 M) | (50.1 M) | (50.1 M) | (50.1 M) | (103.1 M) | (11.8 M) | 273.9 M | 396.4 M | 415.1 M | 430.7 M | 598.3 M | 910.6 M | 963 M | 1 B | 1.1 B |
| PODD | (18.7 M) | 535.3 M | 553.6 M | 685.5 M | 684.7 M | 686.5 M | 744.5 M | 917.3 M | 898.6 M | 749 M | 1.3 B | 1.2 B | 1 B | 1.1 B | 620.4 M |
| ABT | 733.6 M | (9.8 T) | (5.6 B) | (6.8 B) | (8.7 B) | (10.6 B) | (10.8 B) | (10.2 B) | (10 B) | (10.1 B) | (10 B) | (11.8 B) | (15.2 B) | (16 B) | (16.8 B) |
| ALGN | 439 K | 607.2 M | 670.7 M | 729.6 M | 783.4 M | 821.5 M | 864.9 M | 886.4 M | 877.5 M | 906.9 M | 974.6 M | 999 M | 1 B | 1.2 B | 674.1 M |
| SYK | 4.5 M | 1 B | 1.1 B | 1.2 B | 1.3 B | 1.3 B | 1.4 B | 1.5 B | 1.6 B | 1.6 B | 1.7 B | 1.9 B | 2 B | 2.2 B | 2.3 B |
| PACB | 10.9 M | 632.9 M | 20.8 M | 710.7 M | 766.8 M | 820.5 M | 909.1 M | 997.9 M | 1.1 B | 1.1 B | 1.4 B | 2 B | 2.1 B | 2.5 B | 2.7 B |
| NNOX | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 31.7 M | 315 M | 438.8 M | 478 M | 515.9 M | 328.4 M |
| BSX | 33.1 M | 15.9 B | 15.3 B | 15 B | 15 B | 15.1 B | 15.3 B | 15.4 B | 15.6 B | 15.8 B | 17.5 B | 17.7 B | 18 B | 18.4 B | 10 B |
| MDT | 700 K | 2.9 B | 3.2 B | 3.5 B | (1.2 B) | 32.2 B | 29.6 B | 28.1 B | 26.5 B | 26.2 B | 26.3 B | 24.6 B | 24.6 B | 23.1 B | 24.3 B |
Tandem Diabetes Care and related stocks such as DexCom Inc, Inspire Medical Systems, and Shockwave Medical Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| Tandem Diabetes Care | TNDM |
| Classification | Drugs |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 30.63
Check out Tandem Diabetes Performance and Tandem Diabetes Correlation. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Tandem Diabetes technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.